Georgia Eye Partners has expanded its services to include EVO Visian® ICL, a technology recently approved by the FDA, which corrects nearsightedness without the use of glasses or contact lenses.
EVO ICL is an implantable lens positioned just below the surface of the eye to correct nearsightedness (both myopia and myopia with astigmatism). The procedure was designed to be even more comfortable for the patient than earlier versions of the Visian ICL and a faster, more efficient procedure for surgeons than traditional laser surgeries. The EVO ICL is indicated for patients with a prescription between -3.0 up and -20.0 D and can be used to treat astigmatism from 1.0 D to 4.0 D.
“The STAAR EVO ICL lens is a big deal because this improved version of one of our best approaches to correcting nearsightedness and astigmatism is now better than ever,” said Dr. Evan D. Schoenberg, Director of Refractive Services at Georgia Eye Partners. “It provides excellent clarity of vision, even when treating prescriptions twice as high as would be safe with LASIK, does not cause dry eye, and is even reversible if desired. The short, painless procedure has been performed outside the USA over a million times with a 99.4 percent satisfaction rate.
Doctors Schoenberg and Andrew Feinberg, Medical Director of the Eye Surgery Center of Georgia, are the first select doctors throughout the United States to offer the procedure to their patients. There are only 300 doctors (approximately) throughout the country that are currently trained and approved to perform this procedure.
